Leukemia: Dalatumantin anti-Calainadamine and dexamisong are treated with relapsed/incurable multiple myeloma

In pollUX studies, in relapsed/refractic multiple myeloma (RRMM), Dlatumant (D) combined with Amine/Desemisson (Rd) reduced the risk of disease progression or death by 63% compared to Rd and increased the total response rate (ORR).
article introduced the latest efficacy and safety after 3 years of follow-up, and the results were published online in Leukemia.
569 patients received Rd±daratu monoantigen resistance under the approved administration plan (lanadamine, 25 mg, on the 1st-21st day of each 28-day cycle; dexamisson, 40 mg per week).
least residual disease (MRD) is assessed through next-generation sequencing.
results showed that after 44.3 months of medium follow-up, D-Rd extended the progression-free lifetime (PFS) of the intended treatment population and patient subse group (middle 44.5 vs. 17.5 months; HR, 0.44; 95% CI, 0.35-0.55; P -lt; 0.0001).
D-Rd showed higher ORR (92.9 vs 76.4% ;P . 0.0001) and better response, including full reaction or better (56.6 vs 23.2% ;P slt; 0.0001) and MRD negative (10-5;30.4 vs 5.3% ;P slt; 0.0001).
D-Rd, the medium time for the next treatment is extended (50.6 vs 23.1 months; HR, 0.39; 95% CI, 0.31-0.50; P .lt;0.0001).
D-Rd did not reach the mid-PFS (PFS2) (HR, 0.53; 95% CI, 0.42-0.68; P-lt;0.0001) compared to Rd's 31.7 months.
no new security issues have been reported.
, these data support the use of D-Rd in RRMM patients after the first relapse.
。